Skip to the main content.
SERENA-6

Breast Cancer

SERENA-6

About the SERENA-6 Trial



Table of Contents

Major Presentations and Milestones

SERENA-6 Trial design, results, and conclusions

SERENA-6 Sentiments and Criticisms

SERENA-6 Temporal Sentiment Arc

 

SERENA-6 Trial: Major Presentations and Milestones

Primary speakers driving the story

Discussion around SERENA-6 accelerated in early 2025 as clinicians framed the study as a potential “resistance interception” strategy: monitoring for emergent ESR1 mutations on first-line AI + CDK4/6 inhibitor and switching endocrine backbone to camizestrant before radiographic/clinical progression. Sara Tolaney, MD (Dana-Farber Cancer Institute) captured this framing succinctly: “SERENA-6: ctDNA guided approach to switching from AI to camizestrant upon development of ESR1m in combo with cdk4/6i demonstrates improvement in PFS! … Could be a paradigm shift + could introduce ctDNA monitoring into practice.” https://x.com/stolaney1/status/1894714234623197260

At ASCO 2025, the trial’s main-stage visibility was reinforced by society and journal amplification. NEJM highlighted the central message: “switching to camizestrant with a CDK4/6 inhibitor after ESR1-mutation detection (and before disease progression) led to significantly longer progression-free survival.” https://x.com/NEJM/status/1929147672373702906

Several KOLs also pointed to structured “takeaways” content as the community tried to translate the results into practice. Harold J. Burstein, MD, PhD, FASCO (Dana-Farber Cancer Institute) posted: “SERENA-6 trial takeaways from @AngieDemichele.” https://x.com/DrHBurstein/status/1929265891520217143

SERENA-6 Trial Design, Results, and Conclusions

Trial Design:

Based on clinician summaries in the dataset, SERENA-6 is a phase 3 strategy trial in HR-positive, HER2-negative advanced breast cancer testing a ctDNA-guided switch in endocrine therapy: patients on first-line AI + CDK4/6 inhibitor are monitored for emergent ESR1 mutation, and if detected (before progression), switch to camizestrant + CDK4/6 inhibitor versus continuing AI + CDK4/6 inhibitor. Oncology Brothers summarized: “Camizestrant + CDK4/6i vs AI + CDK4/6i for emerging ESR1m before progression.” https://x.com/OncBrothers/status/1929316463921209853

Primary Results (PFS):

The consistent cross-tweet message was that the ctDNA-guided switch strategy improves PFS. Sara Tolaney, MD stated it “demonstrates improvement in PFS!” while emphasizing that downstream endpoints were not yet mature. https://x.com/stolaney1/status/1894714234623197260

NEJM’s meeting post similarly emphasized “significantly longer progression-free survival” with the switch to camizestrant + CDK4/6 inhibitor upon ESR1 mutation detection. https://x.com/NEJM/status/1929147672373702906

Time on 1L therapy / clinical meaning of the PFS gain:

Paolo Tarantino, MD framed the practical interpretation as prolonging time on first-line therapy: “a switch to camizestrant/CDKi vs continuing AI/CDKi can keep pts on 1L treatment for 6.9 months longer.” He also cautioned: “What it does not show (yet): that this strategy improves long term outcomes.” https://x.com/PTarantinoMD/status/1929267181373501616

Key secondary endpoints (immature):

Across tweets, KOLs repeatedly highlighted immaturity of longer-horizon endpoints. Sara Tolaney, MD: “PFS2 + OS immature.” https://x.com/stolaney1/status/1894714234623197260

Key Conclusions:

In the tweet-level discourse captured here, SERENA-6 is viewed as proof-of-concept for molecular progression–guided endocrine switching that improves PFS and extends time on first-line therapy. However, multiple KOLs emphasized that the trial has not yet established improvement in longer-term outcomes (PFS2/OS), and that design choices (e.g., crossover and how PFS2 is defined) will influence how “practice changing” the strategy ultimately becomes.

SERENA-6 Sentiments and Criticisms

Positive Reception (paradigm/implementation potential):

Sara Tolaney, MD: “SERENA-6: ctDNA guided approach… demonstrates improvement in PFS! … Could be a paradigm shift + could introduce ctDNA monitoring into practice” https://x.com/stolaney1/status/1894714234623197260

NEJM (meeting amplification): “switching to camizestrant with a CDK4/6 inhibitor after ESR1-mutation detection… led to significantly longer progression-free survival.” https://x.com/NEJM/status/1929147672373702906

Critical Perspectives (what the trial does/does not prove yet):

Paolo Tarantino, MD (ASCO 2025): “What it does not show (yet): that this strategy improves long term outcomes.” https://x.com/PTarantinoMD/status/1929267181373501616

Stephanie Graff, MD, FACP, FASCO (ASCO 2025) questioned whether the current maturity of endpoints supports immediate practice change: “PFS-2 is immature and crossover was not allowed; given PFS on postMonarch & EMBER-3 combo, it is unclear to me that early switch based on molecular disease is practice changing.” https://x.com/DrSGraff/status/1929271418698498166

Methodologic nuance (PFS2 definition / sequencing imbalance):

Paolo Tarantino, MD relayed a design concern raised by Angie DeMichele, MD: “should PFS2 in SERENA-6 include the post-cami treatment? That creates an imbalance, since it compares patients that received a sequence of 3 treatments to patients that only received 2.” https://x.com/PTarantinoMD/status/1929268164069666990

SERENA-6 Temporal Sentiment Arc

Early 2025 (pre-ASCO: “ctDNA interception” framing)

Primary/KOL tweets:

  • https://x.com/stolaney1/status/1894714234623197260
  • Tone: Cautious optimism—PFS improvement is viewed as meaningful and the ctDNA-guided approach is framed as potentially paradigm-shifting.
  • Shift: Early emphasis on feasibility and the prospect of bringing routine ctDNA monitoring into everyday HR+/HER2− metastatic practice.

June 2025 (ASCO25 + NEJM publication: efficacy signal meets endpoint/design scrutiny)

Primary/KOL tweets:

Overall, SERENA-6 discourse in this dataset shows a classic arc: early enthusiasm for a precision-monitoring strategy, followed by rigorous endpoint and trial-design interrogation once the data are presented and published.

SERENA-6 Professional Resources